Whether, with reference to his reply to question 494 on 20 April 2018 in which he indicated that trial runs to commence with the production of isotopes at Pelindaba resumed on 21 February 2018 after its temporary closing on 17 November 2017, full and uninterrupted production of all previously produced isotopes has been restored since then; if not, what is the position in this regard; if so, what are the relevant details, including dates, production rates and types of isotopes produced;
(2) what (a) was the estimated loss of income suffered by a certain company (name furnished) to date because of the interruption in production and (b) effect has the closure had on the (i) customers and (ii) image of the specified company;
(3) what (a) were the findings of the investigation commissioned by the board of the specified company regarding the closure of the facility and (b) recommendations and/or decisions flowed from the investigation;
(4) whether he has found that the decisions taken by the board and subsequent remedial actions will prevent a reoccurrence of similar unplanned closures; if not, what more needs to be done to achieve certainty regarding future production; if so, what are the relevant details?